ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone650-210-2900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$42.88 million
Profitability
Miscellaneous
Employees76
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable
ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions
What is ChemoCentryx's stock symbol?
ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."
How were ChemoCentryx's earnings last quarter?
ChemoCentryx Inc (NASDAQ:CCXI) issued its earnings results on Monday, May, 6th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.24) by $0.01. The biopharmaceutical company had revenue of $8.33 million for the quarter, compared to analysts' expectations of $11.37 million. ChemoCentryx had a negative net margin of 97.22% and a negative return on equity of 111.15%. View ChemoCentryx's Earnings History.
When is ChemoCentryx's next earnings date?
What price target have analysts set for CCXI?
7 analysts have issued 12-month target prices for ChemoCentryx's stock. Their predictions range from $14.00 to $23.00. On average, they anticipate ChemoCentryx's stock price to reach $18.50 in the next year. This suggests a possible upside of 121.8% from the stock's current price. View Analyst Price Targets for ChemoCentryx.
What is the consensus analysts' recommendation for ChemoCentryx?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 1 hold rating, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ChemoCentryx.
What are Wall Street analysts saying about ChemoCentryx stock?
Here are some recent quotes from research analysts about ChemoCentryx stock:
- 1. According to Zacks Investment Research, "ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. " (5/17/2019)
- 2. HC Wainwright analysts commented, "We base our $23 price target on probability adjusted revenue forecasts for avacopan in AAV and C3G. We use the net present value of our revenue forecast through 2028, apply a 30% probability of success (POS) for avacopan in AAV, a 25% POS for avacopan in C3G, a 3x price/sales multiple, and use our estimated fully diluted year end 2019 net cash of $2.54/share to arrive at our price target. Our P/S multiple of 3x is in-line with ChemoCentryx’s peers that range between 2-5x." (5/7/2019)
Has ChemoCentryx been receiving favorable news coverage?
Media headlines about CCXI stock have trended somewhat positive on Monday, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. ChemoCentryx earned a news impact score of 1.2 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for ChemoCentryx.
Who are some of ChemoCentryx's key competitors?
Some companies that are related to ChemoCentryx include AnaptysBio (ANAB), Insmed (INSM), Zai Lab (ZLAB), Allakos (ALLK), Pacira Biosciences (PCRX), Xencor (XNCR), Portola Pharmaceuticals (PTLA), Tricida (TCDA), Enanta Pharmaceuticals (ENTA), Zogenix (ZGNX), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Prestige Consumer Healthcare (PBH), Madrigal Pharmaceuticals (MDGL) and Cambrex (CBM).
What other stocks do shareholders of ChemoCentryx own?
Who are ChemoCentryx's key executives?
ChemoCentryx's management team includes the folowing people:
- Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman (Age 60)
- Ms. Susan M. Kanaya, Exec. VP, Chief Financial & Admin. Officer and Sec. (Age 56)
- Dr. Rajinder Singh, Sr. VP of Research (Age 52)
- Dr. Jan L. Hillson M.D., Sr. VP of Drug Devel. (Age 66)
- Dr. Markus J. Cappel, Sr. VP, Chief Bus. Officer & Treasurer (Age 58)
Who are ChemoCentryx's major shareholders?
ChemoCentryx's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (9.95%), Wasatch Advisors Inc. (4.27%), Acadian Asset Management LLC (1.34%), Spark Investment Management LLC (0.32%), Marshall Wace LLP (0.23%) and Bank of Montreal Can (0.21%). Company insiders that own ChemoCentryx stock include Geoffrey M Parker, Markus J Cappel, Petrus Bekker, Plc Glaxosmithkline, Rajinder Singh, Roger C Lucas, Susan M Kanaya and Thomas J Schall. View Institutional Ownership Trends for ChemoCentryx.
Which institutional investors are selling ChemoCentryx stock?
CCXI stock was sold by a variety of institutional investors in the last quarter, including Algert Global LLC, Acadian Asset Management LLC, Alps Advisors Inc., Adams Diversified Equity Fund Inc., Fosun International Ltd, Bank of Montreal Can and Rhumbline Advisers. Company insiders that have sold ChemoCentryx company stock in the last year include Geoffrey M Parker, Markus J Cappel, Plc Glaxosmithkline, Rajinder Singh, Susan M Kanaya and Thomas J Schall. View Insider Buying and Selling for ChemoCentryx.
Which institutional investors are buying ChemoCentryx stock?
CCXI stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Wasatch Advisors Inc., Marshall Wace LLP, Spark Investment Management LLC, 361 Capital LLC, Marshall Wace North America L.P., BNP Paribas Arbitrage SA and DekaBank Deutsche Girozentrale. View Insider Buying and Selling for ChemoCentryx.
How do I buy shares of ChemoCentryx?
Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ChemoCentryx's stock price today?
One share of CCXI stock can currently be purchased for approximately $8.34.
How big of a company is ChemoCentryx?
ChemoCentryx has a market capitalization of $484.14 million and generates $42.88 million in revenue each year. The biopharmaceutical company earns $-37,970,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. ChemoCentryx employs 76 workers across the globe.View Additional Information About ChemoCentryx.
What is ChemoCentryx's official website?
How can I contact ChemoCentryx?
ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]
MarketBeat Community Rating for ChemoCentryx (NASDAQ CCXI)
MarketBeat's community ratings are surveys of what our community members think about ChemoCentryx and other stocks. Vote "Outperform" if you believe CCXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CCXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
